close

Agreements

Date: 2018-10-18

Type of information: Production agreement

Compound: tumor infiltrating lymphocyte (TIL)

Company: Iovance Biotherapeutics (USA - CA) MaSTherCell (Belgium), a Orgenesis' subsidiary (USA - NY)

Therapeutic area: Technology - Services

Type agreement:

  • manufaturing - bioproduction

Action mechanism: tumor infiltrating lymphocyte (TIL)

Disease:

Details:

  • • On October 18, 2018, Iovance Biotherapeutics and MaSTherCell, a subsidiary of Orgenesis, announced that the two companies have entered into a new three-year Manufacturing Services Agreement. MaSTherCell will manufacture tumor infiltrating lymphocyte (TIL) for Iovance’s European late-stage clinical trials in its commercial-ready cGMP manufacturing suites.

Financial terms:

Latest news:

Is general: Yes